Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole in adolescents with erosive esophagitis and heartburn
2012-001681-15Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexlansoprazole in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD), sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events during 8-week healing period. Started Jul 2012; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2012-001681-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001681-15.